Myo-inositol May Prevent Gestational Diabetes In PCOS Women
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 83 |
| Sex | Female |
| Age Range | 18-29, 30-44 |
| Body Types | Obese |
Supplementation of myo-inositol throughout pregnancy is associated with less risk of developing gestational diabetes (54% occurrence reduced to 17.2%) in women who also have PCOS. The final odds ratio was 2.4, indicating a more than double risk with placebo relative to inositol at 4,000mg daily
